Shield Therapeutics and Norgine have entered into an exclusive licence agreement in Europe, Australia and New Zealand, under which Norgine will commercialise Feraccru, Shield’s approved product for the treatment of iron deficiency in adults.
GE said that global biotech company BeiGene has selected KUBio, GE Healthcare Life Sciences’ off-the-shelf biomanufacturing facility, to increase its manufacturing capacity for cancer drugs.
Biotechnology company Regeneron will invest about $800m over seven years to expand its laboratory space, manufacturing capacity and warehouse facilities at the company's Rensselaer County campus and create 1,500 new full-time jobs in the greater Capital Region.
The Carlyle Group, a global alternative asset manager, has acquired a minority stake in Ambio, a US-based global peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO), from specialist healthcare fund MVM Partners.
British pharma giant GlaxoSmithKline (GSK) is set to lay off 650 employees in its US operations in line with a global restructuring strategy announced in July this year.
Civica Rx, the initiative earlier known as Project Rx, is the name of a new not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving medications.
Olon, an active pharmaceutical ingredients (API) contract development and manufacturing organization (CDMO) and generics supplier, has acquired a generics chemical operations API manufacturing facility in Mahad, India.
Ireland-based Shire has completed its previously announced $2.4bn sale its Oncology business to French pharmaceutical firm Servier.
Specialty biopharmaceutical firm Emergent BioSolutions has signed an agreement to acquire Adapt Pharma in a deal valued at around $735m.
Drugmaker Lupin has launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets for preventing pregnancy in the US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.